Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 8/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.58 |
| ▸ | TTR | P02766 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | ABL1 | P00519 | 5/20 | 0.51 |
| ▸ | BCR | P11274 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23743170 | 0.91 | CYP1A1 (0.67) | CYP1A1CYP1B1ALOX5PTGS2TTR | |
| SCHEMBL9605438 | 0.83 | CYP1A1 (0.80) | CYP1A1CYP1B1ALOX5PTGS2TTR | |
| SCHEMBL18656029 | 0.81 | RELA (0.57) | CYP1A1CYP1B1MEN1KMT2ACYP1A2 | |
| SCHEMBL9605439 | 0.81 | KDM4E (0.67) | CYP1A1CYP1B1ALOX5PTGS2TTR | |
| SCHEMBL19076183 | 0.80 | CYP1A2 (0.68) | CYP1A1CYP1B1ALOX5PTGS2TTR | |
| SCHEMBL9605436 | 0.76 | CYP1A1 (0.62) | CYP1A1CYP1B1ALOX5PTGS2TTR | |
| SCHEMBL23743198 | 0.76 | CYP1A1 (0.51) | CYP1A1CYP1B1KDM4EMEN1MAPT | |
| SCHEMBL23743201 | 0.76 | TUBB1 (0.60) | CYP1A1CYP1B1PTGS2KDM4EALDH1A1 | |
| SCHEMBL17668126 | 0.75 | APP (0.76) | ALOX5PTGS2TTRMEN1MAPT | |
| SCHEMBL17668127 | 0.75 | APP (0.76) | ALOX5PTGS2TTRMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | CYP1A1 3460/4885CYP1B1 2991/4885ALOX5 1466/4885 |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | CYP1A1 3966/4885CYP1B1 3536/4885ALOX5 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.